99. Chronic intestinal pseudo-obstruction Clinical trials / Disease details


Clinical trials : 4 Drugs : 9 - (DrugBank : 2) / Drug target gene : 1 - Drug target pathways : 4

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-000854-24-IT
(EUCTR)
17/09/202118/10/2021Phase II multicenter clinical trial, with treatment randomly assigned, in which patient nor physician are aware of the assigned treatment, active or placebo, to evaluate efficacy and safety of Velusetrag 15 mg (3 x 5 mg capsule) in patients with Chronic Intestinal Pseudo-Obstruction (CIPO)Velusetrag for the treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A multicenter double-blind, placebo-controlled, cross-over, multiple (n=1) trial. - N/A Chronic intestinal pseudo-obstruction (CIPO) is a rare, severe condition characterized by an impairment of coordinated propulsive activity in the intestinal tract resulting in a clinical picture similar to that of mechanical intestinal obstruction, although in the absence of any lesion occluding the gut. CIPO can be idiopathic or secondary.
MedDRA version: 20.0;Level: SOC;Classification code 10017947;Term: Gastrointestinal disorders;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Velusetrag
Product Code: [TD-5108 hydrochloride]
INN or Proposed INN: Velusetrag
Other descriptive name: THRX-199687 hydrochloride
ALFASIGMA S.P.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
16Phase 2Spain;Belgium;Italy
2JPRN-jRCT2031190137
25/12/201920/11/2019Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 TrialEfficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial Chronic Intestinal Pseudo-obstruction
CIPO, abdominal bloating
Two tablets of the investigational product per dosing (400 mg of rifaximin) or the placebo are orally administered 3 times daily for 4 weeks.Ohkubo HidenoriNULLNot Recruiting>= 20age old< 75age oldBoth12Phase 2Japan
3NCT04118699
(ClinicalTrials.gov)
December 25, 201923/9/2019Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 TrialEfficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Single Center, Randomized, Placebo Controlled, Double-blind Phase 2 TrialChronic Intestinal Pseudo-obstructionDrug: Rifaximin oral tablet;Drug: Placebo oral tabletYokohama City UniversityASKA Pharmaceutical Co., Ltd.Active, not recruiting20 Years74 YearsAll12Phase 2Japan
4NCT00793247
(ClinicalTrials.gov)
December 200818/11/2008Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP)A Double-Blind, Placebo-Controlled, Cross-Over, Multiple (n=1) Trial to Evaluate the Effects of R093877 in Patients With Chronic Intestinal Pseudo-Obstruction (CIP).Chronic Intestinal Pseudo-ObstructionDrug: PRU-PLA-PRU-PLA;Drug: PLA-PRU-PLA-PRU;Drug: PLA-PRU-PRU-PLA;Drug: PRU-PLA-PLA-PRUMovetisNULLCompleted18 YearsN/ABothPhase 2United Kingdom